Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576451 | 1.00 | SCN9A (0.43) | SCN9ASCN3AHDAC1HDAC6TP53 | |
| SCHEMBL1576453 | 1.00 | SCN9A (0.43) | SCN9ASCN3AHDAC1HDAC6TP53 | |
| SCHEMBL13180811 | 0.92 | SCN3A (0.41) | SCN9ASCN3ATP53 | |
| SCHEMBL2626297 | 0.91 | SCN3A (0.48) | SCN9ASCN3ALMNA | |
| SCHEMBL10310788 | 0.91 | SCN3A (0.48) | SCN9ASCN3ALMNA | |
| SCHEMBL2626011 | 0.89 | SCN9A (0.42) | SCN9ASCN3AHDAC1HDAC6LMNA | |
| SCHEMBL10310717 | 0.89 | SCN9A (0.42) | SCN9ASCN3AHDAC1HDAC6LMNA | |
| SCHEMBL14685830 | 0.89 | SCN3A (0.41) | SCN9ASCN3ALMNA | |
| SCHEMBL2626230 | 0.88 | SCN1B (0.49) | SCN9ASCN3ALMNA | |
| SCHEMBL13148770 | 0.88 | SCN1B (0.49) | SCN9ASCN3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | SCN9A 104/4885SCN3A 74/4885HDAC1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.